Structure of Montelukast
CAS No.: 158966-92-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Montelukast is a cysteinyl leukotriene receptor 1 (CysLT1) antagonist widely used for the prevention and treatment of asthma and allergic diseases, with significant clinical applications.
Synonyms: MK0476 free base; MK-476; MK0476
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 158966-92-8 |
Formula : | C35H36ClNO3S |
M.W : | 586.18 |
SMILES Code : | O=C(CC1(CC1)CS[C@H](CCC2=CC=CC=C2C(O)(C)C)C3=CC=CC(/C=C/C4=NC5=CC(Cl)=CC=C5C=C4)=C3)O |
Synonyms : |
MK0476 free base; MK-476; MK0476
|
MDL No. : | MFCD05662278 |
InChI Key : | UCHDWCPVSPXUMX-TZIWLTJVSA-N |
Pubchem ID : | 5281040 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362 |
Description |
Montelukast (MK0476 free base) is a potent, selective, and orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1). It finds utility in asthma and liver injury research. Moreover, Montelukast exhibits antioxidant properties in intestinal ischemia-reperfusion injury, potentially mitigating cardiac damage. Additionally, it reduces eosinophil infiltration in asthmatic airways and holds promise for COVID-19 research[1][2][3][4].
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
HT-29 cells | 50 ng/mL | 24 hours | Reduced IFNγ-induced PD-L1 expression | PMC10265834 |
Lung ILC2 cells | 10^−6 M or 10^−8 M | 6 hours | To evaluate the effect of montelukast on LTD4-induced IL-4, IL-5, and IL-13 production by ILC2. Results showed that LTD4 significantly induced IL-4, IL-5, and IL-13 production by ILC2, and montelukast pretreatment blocked this effect. | PMC3704056 |
Human CD4+ naïve T cells | 0.2 μM, 2 μM, 20 μM | 72 hours | To study the effect of Montelukast on Th17 cell differentiation. Results showed that Montelukast inhibited Th17 cell differentiation in a dose-dependent manner and suppressed the NF-κB signaling pathway. | PMC11008267 |
HaCaT keratinocytes | 10 μM | 48 hours | To evaluate the effect of Montelukast on M5-induced keratinocyte proliferation. Results showed that Montelukast significantly inhibited keratinocyte proliferation and modulated the NF-κB signaling pathway. | PMC11008267 |
MonoMac6 (MM6) cells | 1 μM | 1 hour | To investigate the inhibitory effect of Montelukast on LTD4-induced expression of cytokines and chemokines. Results showed that Montelukast significantly attenuated the LTD4-induced increases in TNF-α and MIP-1α mRNA and protein levels. | PMC5828611 |
SW480 cells | 50 ng/mL | 24 hours | To investigate the activation of PEPT1 transcription by DAC, results showed DAC activated PEPT1 transcription in a dose-dependent manner. | PMC10265834 |
RKO cells | 10 µM | 30 minutes | To test the effect of SQLE knockdown on 5-FU sensitivity, results showed that SQLE knockdown increased the sensitivity of tumor cells to 5-FU treatment. | PMC10265834 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | Xenopus oocytes | Intragastric | 0.2 mg | Once daily for three days | To evaluate the effect of montelukast on LTD4-induced IL-5 production by ILC2. Results showed that LTD4 significantly increased the percentage of IL-5-producing ILC2, and montelukast pretreatment significantly reduced this effect. | PMC3704056 |
BALB/c mice | Hanover Wistar rats | Oral | 30 mg/kg | Once daily, from 1 day before initial infection to Day 6 after infection | To evaluate the effects of montelukast on airway hyperresponsiveness and inflammation after RSV infection. Results showed that montelukast administered during primary infection reduced AHR and inflammation and increased IFN-γ production. | PMC2937239 |
Mice | CD-1 mice | Intraperitoneal injection | 1 mg/kg | Daily administration from D0 to D6 | Montelukast inhibited CYP2C8, and combined treatment with flunarizine further enhanced CNV suppression via suppression of tumor necrosis factor-α expression. | PMC9535696 |
BALB/c mice | ICR mice | Subcutaneous osmotic pump | 1 mg/kg | Daily administration for 90 days | To evaluate the reversal effect of Montelukast on established airway remodeling. Results showed that Montelukast significantly reduced airway smooth muscle thickening and subepithelial collagen deposition, whereas dexamethasone did not. | PMC2662952 |
BALB/c mice | IMQ-induced psoriasis-like model | Topical application and intraperitoneal injection | 30 mg (cream group), 10 mg/kg (i.p. group) | Once daily for 6 consecutive days | To evaluate the therapeutic effect of Montelukast on IMQ-induced psoriasis-like lesions. Results showed that Montelukast significantly reduced PASI scores, decreased inflammatory cell infiltration, and inhibited the NF-κB signaling pathway. | PMC11008267 |
Mice | CaCl2-induced AAA model, AngII-infused ApoE−/− mice model, PPE-induced AAA model | Oral | 0.1 mg/kg/d and 1 mg/kg/d | Once daily for 21 days | To evaluate the preventive and therapeutic effects of Montelukast on AAA development. Results demonstrated that Montelukast significantly reduced aortic dilation, MMP-9 and MIP-1α levels, and showed protective effects in three different AAA models. | PMC5828611 |
Male CD-1 mice | Inflammation-induced encephalopathy of prematurity model | Intraperitoneal injection | 1–30 mg/kg | Twice daily from P1 to P4, once on P5, and continued for a further 5 days | Montelukast was found to attenuate both peripheral and central inflammation, reducing the expression of pro-inflammatory molecules (IL-1β, IL-6, TNF) in the brain. Inflammation induced a reduction in parvalbumin-positive interneuron density in the cortex, which was normalised with high-dose montelukast. The lowest effective dose, 3 mg/kg, was able to improve anxiety and spatial learning deficits in this model of inflammatory injury, and alterations in cortical mean diffusivity were not present in animals that received this dose of montelukast. | PMC9617353 |
Mice | Juvenile mouse brain irradiation injury model | Intraperitoneal injection | 10 mg/kg | Daily for 4 or 14 days | To investigate the protective effects of montelukast on radiation-induced injury in the developing brain. Results showed that montelukast reduced cell death during the acute phase after CIR and decreased microglial activation post-irradiation. However, under normal conditions, montelukast reduced hippocampal cell proliferation. | PMC6039496 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00299910 | Sleep Disordered Breathing | PHASE4 | UNKNOWN | - | Pediatric Sleep Center, Soroka... More >> University Medical Center, Beer-Sheva, Israel Less << |
NCT04818723 | Nephrotic Syndrome | COMPLETED | 2020-05-30 | Department of Pediatric Nephro... More >>logy, The Children's Hospital and Institute of Child Health, Multan, PPunjab, Pakistan Less << | |
NCT01618929 | Bronchial Asthma|Food Allergy|... More >>Children Less << | PHASE4 | COMPLETED | 2025-05-16 | Cansin Sackesen, Ankara, 06100... More >>, Turkey Less << |
NCT01717625 | Premature Birth|Infant, Very L... More >>ow Birth Weight|Bronchopulmonary Dysplasia Less << | PHASE2 | COMPLETED | 2025-10-13 | Ajou university medical center... More >>, Suwon, Woncheon-dong, Yeongtong-gu,, 443-721, Korea, Republic of Less << |
NCT01370187 | Bronchiolitis|Wheezing|Cough | COMPLETED | 2025-06-11 | Hormozgan University of Medica... More >>l Sciences (HUMS), Bandar Abbas, Hormozgan, 79145-3388, Iran, Islamic Republic of Less << | |
NCT02352545 | Cough | PHASE2 | UNKNOWN | 2025-10-15 | Kewu Huang, China, Beijing, 10... More >>0190, China Less << |
NCT02655562 | Coughing | PHASE4 | SUSPENDED | 2025-02-26 | Mingming Jiang, Beijing, China |
NCT02505113 | Portal Vein, Cavernous Transfo... More >>rmation Of Less << | UNKNOWN | - | Department of Radiology, Guang... More >>zhou, Guangdong, 510630, China Less << | |
NCT01951898 | Asthma | PHASE2|PHASE3 | UNKNOWN | 2025-05-15 | Kurume University School of Me... More >>dicine, Kurume, Japan Less << |
NCT01211509 | Bronchiolitis Obliterans|Lung ... More >>Transplantation|Graft Rejection Less << | PHASE4 | COMPLETED | 2025-03-15 | UZ Gasthuisberg, Leuven, 3000,... More >> Belgium Less << |
NCT01754220 | Coughing | PHASE4 | COMPLETED | 2025-12-12 | Clinic of Allergy and Asthma, ... More >>University Hospital "Alexandrovska", Sofia, 1431, Bulgaria Less << |
NCT01027806 | Obstructive Sleep Apnea | PHASE4 | TERMINATED | 2025-08-14 | University of Chicago, Chicago... More >>, Illinois, 60637, United States Less << |
NCT01967498 | Chronic Otitis Media With Effu... More >>sion|Conductive Hearing Loss Less << | UNKNOWN | 2025-05-16 | - | |
NCT00116324 | Asthma | PHASE3 | COMPLETED | 2025-12-06 | Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02115, United States Less << |
NCT00492102 | Bronchopulmonary Dysplasia | PHASE1 | COMPLETED | 2025-06-11 | Good Samaritan Hospital, Cinci... More >>nnati, Ohio, 45220-2489, United States Less << |
NCT05362474 | Diabetic Kidney Disease | PHASE3 | TERMINATED | 2023-06-20 | University of Colorado, Aurora... More >>, Colorado, 80045, United States Less << |
NCT02534467 | Dermatitis, Atopic | PHASE4 | COMPLETED | 2018-12-04 | The Royal Children's Hospital,... More >> Parkville, Victoria, 3052, Australia Less << |
Tags: Montelukast | MK0476 | MK 0476 | MK-0476 | Leukotriene Receptor | cysteinyl | leukotriene | Cysltr1 | asthma | antioxidant | Cysteinyl leukotriene receptor 1 | CysLT1 antagonist | LTC4 | LTD4 | LTE4 | 158966-92-8
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL